Peter Davis, Director and CEO.
Peter has a background in immunology and oncology and has managed research in both large pharma and smaller biotech companies. He has 20 years' experience in the strategic management of small biotech companies focused on oncology research and development.
David Blakey, Consultant
David has over 20 years experience in the discovery and development of therapeutic antibodies. He led AstraZeneca’s first major collaboration on therapeutic antibodies in oncology that identified the anti-PDL-1 antibody durvalumab. He has broad experience in the oncology space and was Chief Scientist Oncology at AstraZeneca for 7 years.
Anderson Ryan, Consultant
Andy is an Associate Professor and Senior Group Leader at Oxford University. He has a strong background in cancer drug research and development though all clinical phases and has hands-on experience of pre-IND, IND and NDA regulatory submissions. Andy also has a substantial international publication record in tumour biology.
David (Dai) Chaplin
Dai is a cancer biologist with over 20 years' senior management experience in large pharma and biotech, including Head of Oncology at Aventis (now Sanofi) and CEO and CSO positions at NASDAQ-listed biotech companies. He has served on the Board of a number of UK- and US-based public and private biotech companies in the oncology space.
Claire currently manages BioCity's investment function making seed stage investments into healthcare companies. Prior to joining BioCity, Claire held leadership roles in R&D and Business Development in several global biopharmaceutical companies (UCB, Genzyme and AstraZeneca) in the UK and the USA, latterly within AstraZeneca’s investment arm, MediVentures.
Georgia is a molecular and cell biologist with 25 years’ in-vitro research experience in early Drug Discovery gained at AstraZeneca. She has been involved in small and large molecule projects across the Inflammation and Oncology disease areas, gaining a wide range of skills and experience in assay development and cell biology across all stages of the drug discovery process.